Safety Considerations with Pharmacological Treatment of Gestational Diabetes Mellitus
Abstract
The number of women with gestational diabetes mellitus (GDM: diabetes first diagnosed in pregnancy) continues to grow, as do the associated risks of antenatal and postnatal complications and the chance of future diabetes and obesity in both mother and offspring. Recent randomised controlled trials have demonstrated clear benefits for intensive management of GDM using lifestyle modification, self blood glucose monitoring, close clinical supervision and, where glycaemia remains inadequately controlled, insulin therapy. More recently, metformin and glibenclamide have been shown to adequately reduce ...
Source: Drug Safety - December 26, 2014 Category: Drugs & Pharmacology Source Type: research
Phenolic excipients of insulin formulations induce cell death, pro-inflammatory signaling and MCP-1 release
Publication date: Available online 6 December 2014 Source:Toxicology Reports Author(s): Claudia Weber , Daniel Kammerer , Bettina Streit , Alexander H. Licht Skin reactions at the infusion site are a common side effect of continuous subcutaneous insulin infusion therapy. We hypothesized that local skin complications are caused by components of commercial insulin formulations that contain phenol or m-cresol as excipients. The toxic potential of insulin solutions and the mechanisms leading to skin reactions were explored in cultured cells. The toxicity of insulin formulations (Apidra, Humalog, NovoRapid, Insuman), ex...
Source: Toxicology Reports - December 7, 2014 Category: Toxicology Source Type: research
Successful pregnancy outcomes in a patient with type A insulin resistance syndrome
ConclusionAdding metformin to the conventional insulin regimen effectively achieved tight glycaemic control with a lower dose of insulin. The mutation of the insulin receptor gene might underlie the intrauterine growth retardation of the newborns. To our knowledge, this is the first report of successful management of diabetes mellitus in a pregnant woman with type A insulin resistance syndrome.This article is protected by copyright. All rights reserved. (Source: Diabetic Medicine)
Source: Diabetic Medicine - December 4, 2014 Category: Endocrinology Authors: B. Enkhtuvshin, S. Nagashima, N. Saito, T. Wakabayashi, A. Ando, M. Takahashi, K. Sakai, D. Yamamuro, S. Nagasaka, H. Tamemoto, S. Ishibashi Tags: Case Report (online only) Source Type: research
Influence of baseline glycemia on outcomes with insulin glargine use in patients uncontrolled on oral agents.
CONCLUSION: When adequate glycemic control is not achieved using OADs in patients with T2DM, initiating insulin glargine is generally less likely to elicit hypoglycemia than initiating NPH, premixed, or prandial insulins, and the benefit-risk balance supports initiating insulin rather than intensification of OAD therapy when baseline HbA1c level is ≥ 8.0%.
PMID: 24918797 [PubMed - indexed for MEDLINE] (Source: Postgraduate Medicine)
Source: Postgraduate Medicine - November 28, 2014 Category: Internal Medicine Tags: Postgrad Med Source Type: research
Comment on Edelman et al. AUTONOMY: The First Randomized Trial Comparing Two Patient-Driven Approaches to Initiate and Titrate Prandial Insulin Lispro in Type 2 Diabetes. Diabetes Care 2014;37:2132-2140.
PMID: 25414398 [PubMed - in process] (Source: Diabetes Care)
Source: Diabetes Care - November 25, 2014 Category: Endocrinology Authors: Rodbard HW, Karolicki B Tags: Diabetes Care Source Type: research
Response to Comment on Edelman et al. AUTONOMY: The First Randomized Trial Comparing Two Patient-Driven Approaches to Initiate and Titrate Prandial Insulin Lispro in Type 2 Diabetes. Diabetes Care 2014;37:2132-2140.
PMID: 25414399 [PubMed - in process] (Source: Diabetes Care)
Source: Diabetes Care - November 25, 2014 Category: Endocrinology Authors: Edelman SV, Liu R, Johnson J, Glass LC Tags: Diabetes Care Source Type: research
Comparative Cost-Effectiveness Analysis of Adding Twice-Daily Exenatide To Insulin Glargine Versus Adding Insulin Lispro To Treat Type 2 Diabetes In Spain
The objective was to estimate the cost-effectiveness in Spain of exenatide BID compared to mealtime bolus insulin lispro, both added to insulin glargine and metformin. (Source: Value in Health)
Source: Value in Health - November 1, 2014 Category: Global & Universal Authors: J. Sánchez-Covisa, M. Capel, S. Baeten, B.G. Verheggen Source Type: research
Premixed Insulin Lispro Versus Insulin Glargine In Type 2 Diabetes: A Meta-Analysis
To systematically review the effectiveness and safety of premixed insulin lispro and insulin glargine in type 2 diabetes. (Source: Value in Health)
Source: Value in Health - November 1, 2014 Category: Global & Universal Authors: Z Lili Source Type: research
The Cost-Effectiveness of Exenatide Bid Versus Insulin Lispro Tid As Add-On Therapy to Titrated Insulin Glargine in Patients With Type 2 Diabetes – An Analysis From The Swedish Health Care Perspective
The objective was to assess the cost-effectiveness of exenatide twice daily (BID) (‘ExBID’) versus insulin lispro three times daily (TID) (‘LisTID’) as add-on therapy to titrated insulin glargine in patients with T2D, from the Swedish health care perspective. (Source: Value in Health)
Source: Value in Health - November 1, 2014 Category: Global & Universal Authors: J. Gordon, P. McEwan, U. Sabale, B. Kartman Source Type: research
Insulin infusion therapy in critical care patients: Regular insulin vs short-acting insulin. A prospective, crossover, randomized, multicenter blind study
The aim of this multicenter, prospective, randomized, crossover trial is to compare, in critical care patients receiving insulin infusion therapy (IIT), the pharmacodynamic of Humulin insulin (Hlin), currently used as “standard of care,” and Humalog insulin (Hlog), a shorter acting insulin formulation. This was measured as extent and duration of the carryover effect of insulin treatment, with the latter calculated as ratio between blood glucose concentration (BGC) reduction during and after IIT. (Source: Journal of Critical Care)
Source: Journal of Critical Care - October 29, 2014 Category: Intensive Care Authors: Federico Bilotta, Rafael Badenes, Simona Lolli, Francisco Javier Belda, Sharon Einav, Giovanni Rosa Source Type: research
Insulin Infusion therapy in critical care patients: regular insulin VS. short acting insulin. A prospective, crossover, randomized, multicenter blind study
The aim of this multicenter, prospective, randomized, crossover trial is to compare, in critical care patients receiving insulin infusion therapy (IIT), the pharmacodynamic of Humulin insulin (Hlin), currently used as “standard of care”, and Humalog insulin (Hlog), a shorter acting insulin formulation. This was measured as extent and duration of the carryover effect of insulin treatment, with the latter calculated as ratio between blood glucose concentration (BGC) reduction during and after IIT. (Source: Journal of Critical Care)
Source: Journal of Critical Care - October 29, 2014 Category: Intensive Care Authors: Federico Bilotta, Rafael Badenes, Simona Lolli, Francisco Javier Belda, Sharon Einav, Giovanni Rosa Source Type: research
Technosphere Insulin (Afrezza): A New, Inhaled Prandial Insulin.
CONCLUSION: TI is a novel inhaled insulin that provides prandial coverage to patients with diabetes, representing an alternative to bolus insulin injections.
PMID: 25313261 [PubMed - as supplied by publisher] (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - October 13, 2014 Category: Drugs & Pharmacology Authors: Nuffer W, Trujillo JM, Ellis SL Tags: Ann Pharmacother Source Type: research
A Randomized Trial of Step-up Treatment with Premixed Insulin Lispro-50/50 vs. Aspart-70/30 in Patients with Type 2 Diabetes Mellitus
Conclusion
Mix50 step-up treatment has a clinical effect in achieving good glycemic control equal to that of BIAsp 30 treatment. (Source: Diabetes Therapy)
Source: Diabetes Therapy - August 27, 2014 Category: Endocrinology Source Type: research
Albiglutide: A New GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes.
CONCLUSION: Albiglutide is the fourth GLP-1 RA approved in the United States. Advantages include once-weekly dosing and fewer gastrointestinal side effects compared with liraglutide, but it is less effective at reducing A1C and weight compared to liraglutide. It has not been compared head to head with other GLP-1 RAs.
PMID: 25136065 [PubMed - as supplied by publisher] (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - August 18, 2014 Category: Drugs & Pharmacology Authors: Trujillo JM, Nuffer W Tags: Ann Pharmacother Source Type: research
Pharmacokinetics of insulin lispro in type 2 diabetes during closed-loop insulin delivery
Closed-loop insulin delivery, also known as ‘the artificial pancreas’ combines a continuous glucose monitoring (CGM) device, a control algorithm, and an insulin pump, and has the potential to transform diabetes care [1,2]. The control algorithm receives, in real-time, sensor glucose concentration and computes the amount of insulin to be delivered by the insulin pump. Clinical trials have demonstrated the safety and efficacy of closed-loop delivery in adults [3], adolescents [4] and pregnant women [5] with type 1 diabetes (T1D). (Source: Computer Methods and Programs in Biomedicine)
Source: Computer Methods and Programs in Biomedicine - July 21, 2014 Category: Bioinformatics Authors: Yue Ruan, Hood Thabit, Kavita Kumareswaran, Roman Hovorka Source Type: research
